Maxi Investments CY Ltd Purchases Shares of 23,800 Twist Bioscience Corporation $TWST

Maxi Investments CY Ltd purchased a new stake in Twist Bioscience Corporation (NASDAQ:TWST) in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 23,800 shares of the company’s stock, valued at approximately $2,449,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Quantbot Technologies LP bought a new stake in Twist Bioscience in the 2nd quarter valued at $1,939,000. Westpac Banking Corp bought a new position in Twist Bioscience during the 2nd quarter worth about $628,000. William Blair Investment Management LLC acquired a new stake in shares of Twist Bioscience in the 2nd quarter valued at about $223,722,000. EP Wealth Advisors LLC acquired a new stake in shares of Twist Bioscience in the 2nd quarter valued at about $492,000. Finally, Ieq Capital LLC bought a new stake in shares of Twist Bioscience in the second quarter valued at about $5,258,000.

Twist Bioscience Price Performance

Shares of NASDAQ TWST opened at $145.59 on Monday. The stock has a market capitalization of $9.13 billion, a price-to-earnings ratio of -65.58 and a beta of 2.14. The business has a 50-day moving average of $100.69 and a 200-day moving average of $70.50. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.67 and a quick ratio of 2.38. Twist Bioscience Corporation has a fifty-two week low of $23.30 and a fifty-two week high of $145.93.

Twist Bioscience (NASDAQ:TWST) last released its earnings results on Monday, August 3rd. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.05). Twist Bioscience had a negative return on equity of 28.64% and a negative net margin of 31.66%.The company had revenue of $118.38 million for the quarter, compared to the consensus estimate of $114.55 million. During the same quarter in the previous year, the company posted $0.33 EPS. The business’s revenue was up 23.2% on a year-over-year basis. As a group, sell-side analysts predict that Twist Bioscience Corporation will post -2.12 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the company. UBS Group set a $89.00 price objective on Twist Bioscience in a research report on Monday, June 15th. Robert W. Baird lifted their target price on Twist Bioscience from $113.00 to $115.00 and gave the company an “outperform” rating in a research report on Tuesday, August 4th. Evercore cut Twist Bioscience from an “outperform” rating to an “in-line” rating and set a $102.00 target price on the stock. in a research note on Monday, July 6th. TD Cowen reaffirmed a “buy” rating on shares of Twist Bioscience in a research report on Monday, August 3rd. Finally, Piper Sandler upped their price target on Twist Bioscience from $85.00 to $115.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 5th. Eight research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Twist Bioscience has an average rating of “Moderate Buy” and a consensus price target of $98.30.

Insider Buying and Selling

In related news, CEO Emily M. Leproust sold 113,318 shares of the firm’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $125.16, for a total value of $14,182,880.88. Following the completion of the transaction, the chief executive officer directly owned 818,938 shares of the company’s stock, valued at approximately $102,498,280.08. This trade represents a 12.16% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Paula Green sold 291 shares of the business’s stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $87.32, for a total transaction of $25,410.12. Following the transaction, the senior vice president owned 120,414 shares in the company, valued at approximately $10,514,550.48. The trade was a 0.24% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders have sold 151,529 shares of company stock worth $17,708,772. 3.08% of the stock is currently owned by company insiders.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.